The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer.
 
Van Karlyle Morris
No Relationships to Disclose
 
Ji Wu
No Relationships to Disclose
 
Liana Adam
No Relationships to Disclose
 
Feng Tian
No Relationships to Disclose
 
Mihai Gagea
No Relationships to Disclose
 
David S. Hong
No Relationships to Disclose
 
David Menter
No Relationships to Disclose
 
Scott Kopetz
Consulting or Advisory Role - Agendia; Amgen; Array BioPharma; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Merrimack; Roche; Sanofi; Sysmex; Taiho Pharmaceutical
Research Funding - Agendia; Amgen; Biocartis; GlaxoSmithKline; Guardant Health; Roche; Sanofi; Sysmex